About Mabgenex
Mabgenex is a Healthcare company based in Hyderabad (India) founded in 2018 by Suresh Chintalapati. mAbGenEx creates antibody platforms for healthcare therapeutics and diagnostics via AI methods. It operates on a B2B model. Its chief executive is Suresh Chintalapati. Mabgenex offers products and services including PrecinAb and OptinAb. Its focus areas include Biotech, Diagnostics, Infectious Diseases and Therapeutics. Its legal entity in India is Mabgenex Private Limited (U74999TG2018PTC129352). Its competitors include Benchsci, Antiverse, Nona Biosciences, EPITOPIC and Deep Biologics and 2 more; 2 of its 7 listed competitors have raised funding.
Company details
mAbGenEx is a biotechnology company based in Hyderabad, India, focusing on antibody discovery and development. They combine traditional experimental methods with AI and ML to produce high-specificity antibodies for therapeutics in oncology and antivenom, as well as diagnostics for infectious diseases. Their platforms, PrecinAb and OptinAb, enable rapid innovation through in vitro and in silico approaches, collaborating with partners to advance healthcare solutions.
- Headquarters Hyderabad, India
- Founders Suresh Chintalapati
- SectorsHealthcare
- Website mabgenex.com
- Social LinkedIn
- Legal Name Mabgenex Private Limited
- Date of Incorporation 27 Dec, 2018
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹25,432
FY 2022
- Net Loss-₹18.1 Lakh
FY 2022 · -7127% margin
- EBITDA-₹18.1 Lakh
FY 2022 · -7120% margin
Associated legal entities of Mabgenex
Mabgenex operates through Mabgenex Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mabgenex Private Limited CIN U74999TG2018PTC129352 | Active | 27 Dec 2018 | Hyderabad, Telangana | ₹0.0 Cr | – | 3 | View details |
Products & Services of Mabgenex
Mabgenex offers a comprehensive portfolio of products and services, including PrecinAb and OptinAb.
AI/ML assisted platform for discovering precision antibodies.
Cell surface display platform for optimized antibody development.
Board of directors of Mabgenex Private Limited (Mabgenex)
Mabgenex Private Limited is the primary company behind Mabgenex. The board of Mabgenex Private Limited currently have 3 directors; the longest-serving is Jaya Laxmi Chintalapati, appointed in 2018. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jaya Laxmi Chintalapati DIN 08315297 | Director | 27 Dec 2018 | 7 yrs 9 mo | Mabgenex Private Limited |
| Suresh Kumar Chintalapati DIN 08315298 | Director | 27 Dec 2018 | 7 yrs 9 mo | Mabgenex Private Limited |
| Ashok Reddy Talusani DIN 09623256 | Director | 30 May 2022 | 4 yrs 4 mo | Mabgenex Private Limited |
People of Mabgenex
1 people are tracked at Mabgenex (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder, CEO | Leadership |
Complete people profiles for Mabgenex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Mabgenex
Figures of Mabgenex Private Limited, the primary company behind Mabgenex, for FY 2022. Revenue was ₹25,432. Net loss was -₹18.1 Lakh (-7127% margin). EBITDA was -₹18.1 Lakh (-7120% margin).
- ₹25,432Revenue · FY 2022
- -₹18.1 LakhNet loss · -7127% margin
- -₹18.1 LakhEBITDA · -7120% margin
- ₹8.2 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Mabgenex Private Limited are on its company page.
Detailed financial statements for Mabgenex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Mabgenex
Mabgenex has 7 listed competitors in our database, 2 of them funded. They include Benchsci, Antiverse, Nona Biosciences, EPITOPIC and Deep Biologics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| benchsci.com | 2015 | Toronto, Canada | $157.73M | – | AI platform used for extracting antibody data from scientific papers. | |
| antiverse.io | 2017 | Cardiff, United Kingdom | $9.58M | 7 | An AI platform for antibody drug discovery is provided. | |
| nonabio.com | 2022 | Cambridge, United States | – | – | Offers antibody discovery, development, and engineering services for biotherapeutics. | |
| epitopic.com | 2016 | Leipzig, Germany | – | – | Provider of cell therapy and antibody services | |
| deepbiologics.ai | 2020 | Toronto, Canada | – | 3 | Provider of an AI-based antibody mining and screening platform for R&D work | |
| abpred.com | 2022 | Aalborg, Denmark | – | – | Provides antibody prediction software for specialized applications. | |
| natiggs.com | 2021 | Ulm, Germany | – | – | Biotech startup discovers and improves natural antibodies for brain disease treatments using AI. |
Detailed competitors of Mabgenex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as Mabgenex (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mabgenex
Mabgenex was founded in 2018.
Mabgenex is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Suresh Chintalapati is the current CEO of Mabgenex. They have also founded this company.
The primary company behind Mabgenex, Mabgenex Private Limited, reported revenue of ₹25,432 for FY 2022.
mAbGenEx is a biotechnology company based in Hyderabad, India, focusing on antibody discovery and development. They combine traditional experimental methods with AI and ML to produce high-specificity antibodies for therapeutics in oncology and antivenom, as well as diagnostics for infectious diseases. Their platforms, PrecinAb and OptinAb, enable rapid innovation through in vitro and in silico approaches, collaborating with partners to advance healthcare solutions.
Mabgenex's top competitors include Antiverse, Benchsci and Deep Biologics.
Mabgenex offers PrecinAb and OptinAb.
Mabgenex operates through Mabgenex Private Limited.
The legal entities of Mabgenex currently have 3 directors, including Ashok Reddy Talusani, Jaya Laxmi Chintalapati, Suresh Kumar Chintalapati.